P53蛋白过表达可预测雌激素受体阳性，早期绝经后乳腺癌对芳香化酶抑制剂治疗的敏感性

doi:10.3969/j.issn.1007-3969.2014.05.006

中国癌症杂志 ›› 2014, Vol. 24 ›› Issue (5): 354-360.doi: 10.3969/j.issn.1007-3969.2014.05.006

P53蛋白过表达可预测雌激素受体阳性，早期绝经后乳腺癌对芳香化酶抑制剂治疗的敏感性

贾晓青¹,洪琪¹,程竞仪²,李剑伟¹,王玉洁¹,莫淼³,邵志敏¹,沈镇宙¹,柳光宇¹

1.复旦大学附属肿瘤医院乳腺外科，复旦大学上海医学院肿瘤学系，上海 200032；
2.复旦大学附属肿瘤医院核医学科，复旦大学上海医学院肿瘤学系，上海 200032；
3.复旦大学附属肿瘤医院临床统计中心，复旦大学上海医学院肿瘤学系，上海 200032

出版日期:2014-05-30 发布日期:2014-05-26
通信作者: 柳光宇　E-mail:liugy123@yahoo.com

Overexpression of P53 is prognostic for aromatase inhibitor resistance in early stage postmenopausal patients with ER-positive breast cancer

JIA Xiao-qing¹, HONG Qi¹, CHENG Jing-yi², LI Jian-wei¹, WANG Yu-jie¹, MO Miao³, SHAO Zhi-min¹, SHEN Zhen-zhou¹, LIU Guang-yu¹

1. Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China;
2. Department of Nuclear Medicine, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China;
3. Department of Epidemiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Published:2014-05-30 Online:2014-05-26
Contact: LIU Guang-yu E-mail: liugy123@yahoo.com

文章分享

摘要/Abstract

摘要：

背景与目的：抑癌基因P53在肿瘤中的研究一直是热点，包括乳腺癌。对于P53基因和乳腺癌预后的研究很多，多数研究表明P53蛋白表达是乳腺癌的不良预后因素之一。而目前对于P53蛋白表达在雌激素受体(estrogen receptor，ER)阳性，早期绝经后乳腺癌对芳香化酶抑制剂(aromotase inhibitors，AI)的敏感性的作用尚无明确结论。本研究旨在探讨P53蛋白表达在ER阳性，早期绝经后乳腺癌对AI治疗敏感性的预测作用。方法：收集2000年1月—2006年12月间复旦大学附属肿瘤医院乳腺外科住院的患者资料共293例。所有患者均接受AI治疗。中位随访时间为72个月(6~140个月)。分析不同P53表达状态对无病生存率(disease freesurvival，DFS)的影响。应用统计学方法进行生存分析及Cox回归模型进行单因素和多因素分析。结果：P53阳性和P53阴性患者的5年生存率分别为78%和89%。多因素回归分析显示P53表达状态(HR=1.729，95%CI：1.038~2.880，P=0.035)、病理分期(HR=2.270，95%CI：1.399~3.681，P=0.001)、组织学分级(HR=2.328，95%CI：1.312~4.133，P=0.004)及年龄(HR=1.988，95%CI：1.511~2.617，P<0.005)是接受AI治疗的早期乳腺癌复发转移的独立危险因素。结论：P53蛋白表达可预测ER阳性，早期绝经后乳腺癌对AI治疗的敏感性；其可能成为决定绝经后激素受体阳性乳腺癌患者治疗策略的关键因素。

关键词: P53, 乳腺癌, 预后, 内分泌耐药

Abstract:

Background and purpose: Tumor suppressor gene P53 has long been studied in tumors, including breast cancer. More studies focused on the relationship between P53 and prognosis of breast cancer and found that P53 overexpression suggested a bad prognosis. However, the effect of P53 on early stage postmenopausal patients with ER-positive breast cancer has not been clarified yet. This study was to investigate the role of P53 plays in aromatase inhibitor (AI) resistance among early stage postmenopausal patients with ER-positive breast cancer patients. Methods: A total number of 293 operable breast cancer patients who received surgical treatment during Jul. 2000 to Jul. 2006 in Fudan University Shanghai Cancer Center were enrolled into this study. All patients received AI treatment. The SPSS 12.0 software was used to estimate the survival rate. Univariate and multivariate analysis were also performed via above software. Results: The median follow-up time is 72 months (6-140 months). The 5 year disease free survival (DFS) of P53 positive and negative were 78% and 89%. The results showed that P53 overexpression (HR=1.729, 95%CI:1.038-2.880, P=0.035), pathological stage (HR=2.270, 95%CI: 1.399-3.681, P=0.001); histological grade (HR=2.328, 95%CI:1.312-4.133, P=0.004); age (HR=1.988, 95%CI:1.511-2.617, P<0.005) were still the independent risk factors of recurrence and metastasis in breast cancer patients treated with AI. Conclusion: P53 overexpression correlated strongly with AI resistance in early stage postmenopausal patients with ER-positive breast cancer patients who were treated with AI and confirmed the relevance of previously described prognostic factors. It is reasonable to take P53 expression into account when we evaluate the risk of breast cancer patients and decide the anti-cancer treatment strategy.

Key words: P53, Breast cancer, Prognosis, Endocrine resistance

贾晓青,洪琪,程竞仪,李剑伟,王玉洁,莫淼,邵志敏,沈镇宙,柳光宇. P53蛋白过表达可预测雌激素受体阳性，早期绝经后乳腺癌对芳香化酶抑制剂治疗的敏感性[J]. 中国癌症杂志, 2014, 24(5): 354-360.

JIA Xiao-qing, HONG Qi, CHENG Jing-yi, LI Jian-wei, WANG Yu-jie, MO Miao, SHAO Zhi-min, SHEN Zhen-zhou, LIU Guang-yu. Overexpression of P53 is prognostic for aromatase inhibitor resistance in early stage postmenopausal patients with ER-positive breast cancer[J]. China Oncology, 2014, 24(5): 354-360.

[1]	伍雯, 张若昕, 翁俊勇, 马延磊, 蔡国响, 李心翔, 杨永志. 探索阳性淋巴结比率在ypⅢ期结直肠癌患者中的预后价值及预测模型的建立[J]. 中国癌症杂志, 2024, 34(9): 873-880.
[2]	徐睿, 王泽浩, 吴炅. 肿瘤相关中性粒细胞在乳腺癌发生、发展中的作用研究进展[J]. 中国癌症杂志, 2024, 34(9): 881-889.
[3]	肖锋, 许桐林, 朱琳, 肖静文, 吴天祺, 顾春燕. M1型肿瘤相关巨噬细胞在肝细胞癌组织中浸润的意义[J]. 中国癌症杂志, 2024, 34(8): 726-733.
[4]	曹晓珊, 杨蓓蓓, 丛斌斌, 刘红. 三阴性乳腺癌脑转移治疗的研究进展[J]. 中国癌症杂志, 2024, 34(8): 777-784.
[5]	张剑. 关于女性乳腺癌患者绝经状态判断两个关键问题的临床思考[J]. 中国癌症杂志, 2024, 34(7): 619-627.
[6]	姜丹, 宋国庆, 王晓丹. 乳腺癌中线粒体功能障碍与CPT1A/ERK信号转导通路共同调节乳腺癌恶性行为的机制研究[J]. 中国癌症杂志, 2024, 34(7): 650-658.
[7]	董涧桥, 李坤艳, 李菁, 王斌, 王艳红, 贾红燕. SIRT3通过去乙酰化YME1L1诱导乳腺癌内分泌治疗耐药的作用机制研究[J]. 中国癌症杂志, 2024, 34(6): 537-547.
[8]	唐楠, 黄慧霞, 刘晓健. 利用单细胞测序和转录组测序建立结直肠癌免疫细胞的9基因预后模型[J]. 中国癌症杂志, 2024, 34(6): 548-560.
[9]	郝弦, 黄建军, 杨文秀, 刘晋廷, 张军红, 罗钰蓓, 李青, 王大红, 高玉炜, 谭福云, 薄莉, 郑羽, 王荣, 冯江龙, 李静, 赵春华, 豆晓伟. 乳腺癌原代细胞系为药物筛选和基础研究提供癌症新模型[J]. 中国癌症杂志, 2024, 34(6): 561-570.
[10]	张若昕, 叶紫岚, 翁俊勇, 李心翔. 高龄与Ⅱ期结直肠癌患者预后不良的相关性研究[J]. 中国癌症杂志, 2024, 34(5): 485-492.
[11]	中国抗癌协会乳腺癌专业委员会. 中国早期乳腺癌卵巢功能抑制临床应用专家共识（2024年版）[J]. 中国癌症杂志, 2024, 34(3): 316-333.
[12]	张琪, 修秉虬, 吴炅. 2023年中国乳腺癌重要临床研究成果及最新进展[J]. 中国癌症杂志, 2024, 34(2): 135-142.
[13]	张思源, 江泽飞. 2023年改变晚期乳腺癌临床实践的重要研究成果及进展[J]. 中国癌症杂志, 2024, 34(2): 143-150.
[14]	王昭卜, 黎星, 于鑫淼, 金锋. 2023年改变早期乳腺癌临床实践的重要研究成果及进展[J]. 中国癌症杂志, 2024, 34(2): 151-160.
[15]	罗扬, 孙涛, 邵志敏, 崔久嵬, 潘跃银, 张清媛, 程颖, 李惠平, 杨燕, 叶长生, 于国华, 王京芬, 刘运江, 刘新兰, 周宇红, 柏玉举, 谷元廷, 王晓稼, 徐兵河, 宋礼华. AK-HER2与参照药治疗HER2阳性转移性乳腺癌患者的疗效、体内代谢特征、安全性和免疫原性比较：一项多中心、随机、双盲Ⅲ期等效性临床试验[J]. 中国癌症杂志, 2024, 34(2): 161-175.

P53蛋白过表达可预测雌激素受体阳性，早期绝经后乳腺癌对芳香化酶抑制剂治疗的敏感性

Overexpression of P53 is prognostic for aromatase inhibitor resistance in early stage postmenopausal patients with ER-positive breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价